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Abstract 
Objective: The objective of this systematic review is to determine whether or not the oral 
Phosphodiesterase inhibitor Tadalafil improves exercise capacitance in those over 12 years with 
pulmonary hypertension. 
Study Design: Review of three primary research materials published in English language in 
2009. 
Data Sources: Randomized, controlled, double blind clinical trials found using PubMed, OVID 
and COCHRANE databases. 
Outcome measured: Trials measured 6-minute walking distance and health related quality of 
life measurements which included: SF-36 (a measure of self reported health status), and the EQ-
5D (a patient reported health related quality of life measure), WHO functional class, clinical 
worsening, and hemodynamic measurements. 
Results: Two of the randomized controlled trials included in this review showed that tadalafil is 
effective at improving exercise capacitance in patients with pulmonary hypertension. The trials 
showed patients had an improvement in their 6-minute walking distance, self reported health 
status and quality of life, and improvement in time to clinical worsening. The trial conducted by 
Fischler et al showed that tadalafil was not effective at improving exercise capacitance in 
patients with high altitude pulmonary edema in comparison with dexamethasone.  
Conclusions: Tadalafil 40 mg is an effective monotherapy for increasing exercise capacitance 
and improving health related quality of life in patients with pulmonary hypertension. In the Galie 
et al and Pepke-Zaba et al studies, tadalafil was found to improve exercise capacitance and 
quality of life in patients with pulmonary arterial hypertension. However, in the Fischler et al 
study, dexamethasone, not tadalafil improved exercise capacity in patients with high al2titude 
pulmonary edema.  
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Introduction: 
Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder where the 
pulmonary arterial pressure is persistently elevated, eventually leading to right sided heart failure 
and death.2 This disorder can be grouped into two main categories: primary and secondary PAH. 
Primary pulmonary hypertension is considered to be idiopathic because it arises without a family 
history or any underlying condition. Whereas, secondary PAH is due to some sort of underlying 
disease such as: collagen vascular disease, HIV infection, congenital heart disease, left-sided 
heart failure, pulmonary embolism, portal hypertension, or sarcoidosis. It is estimated that 
idiopathic PAH effects about 0.1-0.2% of the population with the mean age at diagnosis being 50 
years old; furthermore, more women are affected by PAH than men, with a ratio of 2:1.4 
Moreover, it is estimated that 2-4% of patients with chronic liver disease, 0.5% of patients with 
HIV and about 23-25% of patients with mixed connective tissue diseases have secondary PAH. 
However, of the people who are diagnosed yearly with pulmonary hypertension, it is estimated 
that only about 15,000 to 25,000 are diagnosed and treated appropriately.4   
The exact cause and pathogenesis of this disease is unknown; however, it is thought that 
several different factors play a role in the vasoconstriction and narrowing of the pulmonary 
vasculature. More specifically, some sources of PAH include: vascular cell proliferation and 
apoptosis, influx of cellular inflammation, excess vasoconstriction, and in situ thrombosis.2,3  
Normal pulmonary arterial pressure is 12-16 mmHg; however, this disease is considered 
pathologic when the mean arterial pressure exceeds 25 mmHg at rest over an extended period of 
time.4  
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Patients who have PAH usually will present with non-specific symptoms such as chest 
pain, dyspnea, fatigue, peripheral edema, cyanosis and syncope2,3  The World Health 
Organization has come up with its own classification of PAH which includes: Class I: Patients 
with PAH but without resulting limitation of physical activity. Ordinary physical activity does 
not cause any limitation. Class II: Patients with PAH resulting in slight limitation of physical 
activity. They are comfortable at rest, but ordinary physical activity causes limitative symptoms 
such as: dyspnea, fatigue, chest pain, or near syncope. Class III: Patients with PAH resulting in 
marked limitation of physical activity. They are comfortable at rest; however, less than ordinary 
activity causes limitation symptoms. Class IV: Patients with PAH who are unable to carry out 
any physical activity without symptoms. These patients manifest signs of right-heart failure and 
have limitative at rest which are increased with physical activity.4 
Unfortunately, at the present time there is no cure for PAH. However, there are currently 
three classes of drugs which have been approved for the treatment of PAH in the United States 
which include: prostanoids (epoprostenol, treprostinil,iloprost), endothelin receptor antagonists 
(bosentan, ambristan, sitaxsentan), and phosphodiesterase type 5 inhibitors (sildenafil and 
tadalafil).3,7 Other conventional therapies such as calcium channel blockers, digoxin, warfarin, 
oxygen and diuretics may also be used to aide in the treatment of PAH; but, the only definitive 
treatment of PAH is lung transplantation at this time.3,7 An exact number for the total healthcare 
cost of PAH has not been indentified; however, the annual drug costs for Sildenafil, Bosentan, 
Ambrisentan, and Iloprost is $12,761, $55,890, $56,736, and $92,146, respectively.5 
Furthermore, an estimate of patients hospitalized with PAH was not available within the past few 
years, but between 2000 and 2002, 807,000 patients were hospitalized with PAH and in 2002 
PAH led to 260,000 hospital visits in the United States6 
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Objective:  
The objective of this systematic review is to determine whether or not the 
Phosphodiesterase inhibitor Tadalafil improves exercise capacitance in those over 12 years old 
with pulmonary hypertension. 
Methods: 
 The studies used for this review were selected based on the following criteria. The patient 
population included those who were over 12 years of age with symptomatic pulmonary arterial 
hypertension. The diagnosis of PAH included: a resting mean pulmonary artery pressure ≥ 25 
mmHg, pulmonary wedge pressure ≤ 15 mmHg, and pulmonary vascular resistance ≥ 3 Wood 
units. The intervention used was oral tadalafil. The treatment groups were compared to placebo 
groups who received a visually matched placebo. The outcomes measured were exercise 
capacitance with measurement of the 6-minute walk distance (6-MWD), health related quality of 
life measures (measured by the SF-36 and ED-50), WHO functional class, Borg dyspnea score, 
and hemodynamic measurements, all of which can qualify as patient oriented evidence that 
matters (POEMs). Furthermore, all three studies were randomized double blind, placebo 
controlled clinical trials.  
 In research conducted by Fischler et al, 23 patients aged age 44 ± 10 years with a body 
mass index of 24.5 ± 3.0 kg/m2 and a history of high altitude pulmonary edema (HAPE) were 
enrolled into the trial. The patients were randomized in a double blind fashion and were given 
either 10 mg of tadalafil twice a day,  8 mg of dexamethasone twice a day, or placebo twice a 
day the morning before their ascent to  high altitude. On day one of the ascent cycle ergometer 
cardiopulmonary exercise test (CPET) was performed and on day two an echocardiograph 
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examination was performed which both allowed for hemodynamic measurements to be taken. 
Patients were excluded from the study if they spent more than four nights above 2,500 meters 
within 30 days before study entry. 
Four hundred and five patients over the age of 12 years old with PAH that was 
idiopathic/heritable or related to anorexigen use, connective tissue disease, HIV infection, 
congenital systemic-to-pulmonary shunts were part of the Galie et al study. The patients were 
either treatment naïve or on background therapy with bosentan, an endothelin receptor 
antagonist.  Furthermore, patients were continued on bosentan throughout the study if they were 
on a maximum stable dose of 125 mg twice daily for a minimum of 12 weeks at the time of 
screening. The majority of the patients had symptoms in WHO functional class II or III and 
about 53% of the patients were on background bosentan therapy. The patients were randomized 
into placebo and treatment groups, those in the treatment group received either tadalafil 2.5, 10, 
20, or 40 mg orally once daily. Outcomes included: the change from baseline in the 6-MWD, 
changes in the WHO functional class, Borg dyspnea score, time to clinical worsening, and health 
related quality of life measurements, via the SF-36 and EQ-5D. Patients were excluded from this 
study if the patient had a 6-minute walk distance (6-MWD) of <150 m or >450 m or if they were 
previously treated with intravenous epoprostenol, intravenous or inhaled iloprost, or 
subcutaneous treprostinil. 
The Pepke-Zaba et al study lasted for 16 weeks and included 405 patients over the age of 
12 years old with symptomatic PAH. The majority of the patients included in this study had PAH 
that was idiopathic/familial, a WHO functional class of II or III, and were mostly female. 
Furthermore, patients who were already on background bosentan therapy of a dose of 125 mg 
twice daily for 12 weeks were able to continue that along with the study medication. Patients 
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were randomized into placebo and experimental groups, with experimental group having 
received either tadalafil 2.5, 10, 20, or 40 mg once daily. The main outcome of this study was 
measuring the mean change from baseline in the 6-MWD in order to evaluate exercise 
capacitance, along with patient reported health related quality of life measurements, through the 
SF-36 and EQ-5D.  These outcomes were measured at baseline and then weeks 8 and 16. If 
patients had a 6-MWD <150 and >450 meters or were treated previously with epoprostenol, 
iloprost, treprostinil, sitaxsentan, ambrisentan, and sildenafil they were excluded from the study. 
Key words used in searches were Pulmonary Hypertension, Tadalafil. All articles were 
published in the English language and in peer-reviewed journals. This author personally did the 
article search in PubMed, OVID and Cochrane database. Inclusion criteria were: patients over 
the age of 12, randomized controlled trials, articles that were not previously published in a meta-
analysis or systematic review, had POEM outcomes, and articles that were published between 
1996 and the present. Exclusion criteria were studies with patients under 12 years old, articles 
previously used in a meta-analysis or systematic review and studies published before 1996. Of 
the three papers, they all reported p-values of statistical significance; however, the Fischler et al 
study was the only one to report a RRR, ARR, and NNT.  
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Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria  
W/D Interventions 
Fischler1 
(2009) 
Double 
blind 
RCT 
29 44 ± 10 
years 
age 44 ± 10 years 
with a body mass 
index of 24.5 ± 
3.0 kg/m2; a 
history of HAPE  
 
spending more 
than four nights 
above 2,500 
meters within 
30 days before 
study entry 
 
6 Regimen of 
Tadalafil 10 
mg bid, 
dexamethason
e 8 mg bid, or 
placebo 
starting the 
day before 
ascent  
 
Galie2 
(2009) 
Double 
blind 
RCT 
405 >12 
years 
old 
Patients were at 
least 12 years of 
age and had 
symptomatic 
pulmonary 
arterial  
hypertension  
 
Patients with a 
6-minute walk 
distance (6-
MWD) of <150 
m or >450 m, 
treatment with 
intravenous 
epoprostenol, 
intravenous or 
inhaled iloprost, 
or subcutaneous 
treprostinil was 
prohibited 
 
3 Regimen of 
Tadalafil 2.5 
mg, 10 mg, 20 
mg, 40 mg  or 
placebo orally 
once daily  
 
Pepke-
Zaba3 
(2009) 
Double 
blind 
RCT 
405 >12 
years 
old 
Patients were at 
least 12 years of 
age and had 
symptomatic 
pulmonary 
arterial  
hypertension  
 
6-MWD test 
distance <150 
and >450 
meters, 
treatment with 
epoprostenol, 
iloprost, 
treprostinil, 
sitaxsentan, 
ambrisentan, 
and sildenafil 
 
0 Regimen of 
Tadalafil 2.5 
mg, 10 mg, 20 
mg, 40 mg  or 
placebo orally 
once daily 
 
 
Outcomes Measured:  
Table 1. Characteristics of Studies for systematic review of Tadalafil on exercise capacitance 
with PAH 
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The Fischler et al study measured exercise capacitance by performing Cycle Ergometer 
Cardiopulmonary exercise test (CPET) and an echocardiography and calculating hemodynamic 
measurements at low and high altitudes. The CPET was performed on Day 1 about 4 to 6 hours 
after the patients’ arrival at 4, 559 m and an echocardiography was performed on the second day. 
The CPET measured O2-uptake kinetics, oxygen saturation, heart rate and blood pressure; 
whereas the echocardiogram measured the pulmonary artery pressure. Furthermore, assessment 
of HAPE (high altitude pulmonary edema) was defined as previously reported and the 
development of AMS (acute mountain sickness) via the Lake Louise consensus scoring system. 
The Galie et al study measured exercise capacitance via the change from baseline in the 
6-MWD, changes in the WHO functional class, and the Borg dyspnea score. Health related 
quality of life was measured using the SF-36 and the EQ-5D. The SF-36 consists of 36 items 
which represent one of the following topics: physical functioning, role limitations due to physical 
problems, bodily pain, general health perception, vitality, social functioning, role limitations due 
to emotional problems, and mental health. The EQ-5D has two parts, which include 5 questions 
that assess mobility, self care, usual activity, pain/discomfort and anxiety/depression. The 6-
MWD, WHO functional class, and Borg dyspnea score were all measured at baseline and at 
weeks 4, 8, 12, and 16. Furthermore, Pepke-Zaba et al measured exercise capacitance by using 
the 6-minute walk test and also measured self-reported health status and quality of life measures 
via the SF-36 and EQ-5D which were all measured at baseline and then again at weeks 8 and 16. 
Results: 
 All three of the articles were presented as double blind, randomized control trials. The 
Fischler et al study presented their results as dichotomous data; whereas, the Galie et al and 
Erin Chesnavich 
Tadalafil and exercise capacitance with PAH  8 
Pepke-Zaba et al studies presented their results as continuous data. Fischler et al conducted 
research with 23 participants, three women and twenty men, in order to evaluate the tadalafil and 
improving exercise capacitance in patients who developed HAPE. Six people within this study 
had to be excluded because of technical problems with the equipment. The Galie et al study 
conducted research on a total of 405 patients with only 341 patients completing the entire 16 
week study. Three patients died during the study; one patient died in the placebo group due to 
PAH progression, another in the 10 mg tadalafil group died suddenly and the third death was in 
the tadalfil 20 mg group which was due to histiocytosis hematophagic syndrome. Lastly, the 
Pepke-Zaba study contained a total of 405 patients; however, there was no definite information 
presented within the study as to how many patients did not finish the study.  
The Fischler et al study evaluated the effects of dexamethasone, tadalafil and placebo on 
improving exercise capacitance at high altitude. This study found that dexamethasone improves 
exercise capacity and partially limits hypoxia-induced pulmonary hypertension at 4,559 meters 
in HAPE susceptible individuals. Whereas, tadalafil did not significantly improve exercise 
capacitance and did not significantly limit instances of hypoxia-induced pulmonary 
hypertension. Dexamethasone significantly improved maximum oxygen uptake and oxygen 
kinetics compared with placebo (P<0.05); however, peak oxygen saturation did not differ 
significantly between the three treatment groups. Blood pressure did not change among the three 
groups, but there was a significant increase in heart rate among all three groups, which was 
significantly lower in the dexamethasone group than the other two groups (p < 0.01). 
Furthermore, echocardiography showed that dexamethasone revealed lower pulmonary artery 
pressures in comparison to placebo. Acute mountain sickness scores did not differ between the 
three groups on day 1; however, on day 2 the dexamethasone group had statistically significant 
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lower scores with a p value of <0.01. The RRR was calculated as -84% and the ARR was -74%. 
The NNT was determined as -1.4 with a p-value of 0.001. The negative value of NNT indicates 
that if two people were treated with tadalafil, one less person in the tadalafil treatment group will 
have increased exercise capacitance compared to those people in the dexamethasone treatment 
group.  
Table 2. Treatment effects of Tadalafil on exercise capacitance in PAH 
Study Relative risk 
reduction 
Absolute risk 
reduction 
Number needed 
to treat 
p-value 
Fischler et al, 20091 -84% -74% -1.4 0.001 
 
Galie et al researched the efficacy of tadalafil on improving exercise capacitance and 
quality of life in patients with PAH. In this study, exercise capacitance was measured using the 
6- MWD through comparing the mean change from baseline between the experimental and 
placebo groups. Tadalafil 10, 20, and 40, not the 2.5 mg group, notably improved the 6-MWD in 
comparison to the placebo group. However, only the tadalafil 40 mg group achieved statistical 
significance with a p-value < 0.01. Furthermore, in the 40 mg tadalafil treatment group, the mean 
change in the 6-MWD was 44 m in treatment naïve individuals (CI 95%, P<0.01) and 23 m in 
individuals on background bosentan therapy (CI 95%, P=0.09). There was no statistically 
significant difference amongst the experimental and placebo groups with improvement or 
worsening in WHO functional class. Moreover, time to clinical worsening was significantly 
improved in the tadalafil 40 mg group (P=0.041) when compared with placebo and the overall 
incidence of clinical worsening was reduced in the tadalfil 40 mg group.  
Furthermore, there was no difference in changes in the Borg dyspnea score between 
treatment and placebo groups. However, statistically significant improvements in quality of life 
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were seen in 6 out of the 8 domains in the SF-36 (P<0.01) and all sections of the EQ-5D in the 
tadalafil 40 mg group (P<0.02).  Throughout this 16 week study, the most common adverse 
events seen with taking tadalafil were: headache, myalgia, and flushing. 
The objective of the Pepke-Zaba study was to study the effect of tadalafil on health 
related quality of life measures in patients with PAH. The mean change in the 6-MWD was 
greater for all patients that were treated with tadalafil in comparison with the placebo group; 
however, the mean change was greatest in the tadalafil 40 mg group. The pre-specified value of 
statistical significance (p < 0.01) was only achieved in the tadalafil 40 mg group. Furthermore, 
only the tadalafil 40 mg group showed improvement over placebo in six out of the eight domains 
of the SF-36 along with a significant change from baseline to week 16 on the EQ-5D score. The 
most common adverse events encountered during this study were headache, myalgia, and 
flushing, which were described as mild to moderate in severity. 
Discussion: 
Tadalafil is the second phospodiesterase inhibitor to be used for the treatment of PAH 
and is currently FDA approved in the United States for treatment of erectile dysfunction under 
the trade name Cialis. However, for the treatment of PAH, it is marketed as Adcirca. The most 
common adverse effects which have been experienced while taking tadalafil include: flushing, 
headache, dyspepsia, myalgia, extremity pain, upper respiratory infection, and nasopharyngitis. 
Also, some contraindications to using tadalafil include: hypersensitivity reaction to tadalafil and 
concomitant use with other organ nitrates.8 In the Galie et al and Pepke-Zaba et al studies, 
tadalafil 40 mg showed statistically significant improvement in the outcomes measured. Tadalafil 
40 mg improved the 6-MWD, quality of life measurements, including both the SF-36 and the 
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EQ-5D, and reduced time to clinical worsening. However, within the Fischler et al study, 
tadalafil did not significantly improve exercise capacitance at a high altitude and did not 
significantly limit instances of hypoxia-induced pulmonary hypertension or acute mountain 
sickness.  
A limitation of these three trials was the length of studies.  The patients were not 
followed for longer than 16 weeks; therefore, long term efficacy and safety were not able to be 
properly assessed. Another limitation within the Galie et al and Pepke-Zaba studies include 
patients that were on background bosentan therapy while in the trials because this may have 
altered the results. A final limitation of this review on tadalafil is that two of the studies were 
performed at sea level and the Fischler et al study was conducted at a high altitude; therefore, an 
equivalent comparison of tadalafil could not be evaluated.  
Conclusion: 
 Even though tadalafil was not effective in increasing exercise capacitance in patients who 
experience high altitude pulmonary edema, the other two studies demonstrated that tadalafil 40 
mg is an efficient monotherapy for increasing exercise capacitance in patients older than 12 years 
old with pulmonary hypertension. Tadalafil was effective at improving the 6-minute walk 
distance, quality of life measurements, including both the SF-36 and the EQ-5D, and reducing 
time to clinical worsening. In order to fully examine the long term benefits and outcomes of 
tadalafil, a larger subset of patients who are followed for a longer period of time is needed.  
Further research would include targeting the diseases in which patients develop secondary PAH 
and formulating disease specific therapies. Another research opportunity would be to find a cure 
for PAH since this is a chronic and progressive condition.  
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